Onset: None acute. This is the single most important user-experience fact about cordyceps — there is no "felt" first dose. Stimulant-expecting users routinely report nothing for the first 7-14 days and quit.

Plateau: Around week 3-4 of consistent daily dosing, athletes typically report a modest "easier breathing" sensation on aerobic work, slightly faster perceived recovery between intervals, and (less consistently) improved morning energy. The dopamine.club aggregate flags "energy" (200 reports) and "focus" (122 reports) as the top community-reported effects — note that these may be partly placebo-driven, but they're consistent across blends.

Honest variability:

• ~50% of users report a clear "I notice something" effect after 3-4 weeks at adequate dose (2-3 g/day, real militaris fruiting body).
• ~30% report nothing distinguishable from placebo.
• ~20% report mild side effects without benefit (GI upset, mild dry mouth, restlessness) — usually mycelium-on-grain products contaminated with starch, not true cordyceps.

Not a stimulant. No racing heart, no jitters, no acute focus boost. If a "cordyceps" product gives you stimulant-like feelings within 30-60 minutes, it's probably contaminated with caffeine or another adulterant — this is well-documented in the supplement adulteration literature.

MMA-specific subjective: Most likely felt effect for a 20yo MMA athlete is on the cardio side — easier breathing through 5-minute rounds in week 4-5 of consistent use, and slightly faster recovery between sparring sessions. Not a fight-day tool. Won't change punch power, grip strength, or anaerobic capacity meaningfully.

Tolerance: No documented receptor-level tolerance in human or animal models. The mechanism — slow mitochondrial + immune adaptation — doesn't predict tolerance. Long-term studies (12+ weeks) consistently show maintained efficacy.

Anecdotal tolerance reports ("worked great for 6 weeks then stopped doing anything") are usually one of: (1) regression of placebo/novelty effect; (2) product switch to lower-grade mycelium; (3) confounding sleep, training, or stress changes masking the benefit; (4) genuine adaptation in a small subset.

Cycling recommendation: None needed for healthy daily use. Continuous dosing 8-12 weeks at a time, with optional 2-4 week breaks between training blocks if you want to re-test responder status. The community-data block in this file (114-day median duration across 92 repeat users) shows that the modal cordyceps user runs it continuously for 3-4 months at a time — that's a reasonable pattern.

Reset protocol: If a perceived "stopped working" period sets in, 2 weeks off followed by resumption at the same dose is more useful than dose escalation.

Synergistic with

• reishi (Ganoderma lucidum): Most-combined partner in the community data (229 co-mentions). Reishi covers the recovery axis (lactate clearance, urea reduction in Shu 2025 meta) while cordyceps covers the aerobic-capacity axis. Real Mushrooms 5-Defenders blend is a clean way to run this. Useful for Dylan in heavy-cardio MMA blocks.
• lion's mane: Common stack partner. No direct interaction; lion's mane targets BDNF / cognitive support, cordyceps targets aerobic capacity. Different mechanisms, no overlap.
• rhodiola rosea: Common stack (166 co-mentions). Both are anti-fatigue adaptogens with non-overlapping mechanisms (rhodiola hits monoamines + cortisol; cordyceps hits adenosine + mitochondria). Earnest 2004 used this combo unsuccessfully but at too short a duration.
• ashwagandha: 166 co-mentions. Sleep + cortisol modulation pairs cleanly with cordyceps's training-load support.
• caffeine: 168 co-mentions. No direct interaction. If using both, dose cordyceps in the morning with coffee — bioavailability is fine, and it sidesteps having to remember a second timing slot.
• omega-3 (EPA/DHA): 181 co-mentions. Anti-inflammatory recovery support, no interaction.
• vitamin D3: 186 co-mentions. Immune-axis synergy plausible but not formally tested.

Avoid stacking with

• Anticoagulants (warfarin, DOACs — apixaban, rivaroxaban): Theoretical additive bleeding risk. See community-data interactions block for the AI-seeded mechanism summaries. No human case reports, but the mechanism is plausible. Skip the stack if Dylan is on an anticoagulant for any reason (he's not).
• Antiplatelets (aspirin daily, clopidogrel): Same theoretical concern. For a 20yo MMA athlete this almost never applies.
• High-dose NAC continuously: Cordycepin's apoptosis-inducing effects in cell models are ROS-dependent. NAC (a ROS scavenger) blunts this in vitro. Practical relevance for an athlete is essentially zero — Dylan is not using cordyceps for its anti-tumor effects. The 116 community posts flagging this are about cancer-adjunct populations, not athletes. Run NAC and cordyceps together without concern for general health purposes.
• Immunosuppressants (post-transplant, certain autoimmune meds): Cordyceps activates NK cells and macrophages. Theoretical concern, not relevant to Dylan.
• High-dose mTOR inhibitors (rapamycin) for longevity protocols: Additive mTOR suppression. Not a fight-camp concern.

Neutral / safe co-administration

• All of Dylan's V4 stack (creatine, magnesium, NAC, citicoline, PS, DHA, curcumin, rhodiola, theanine, glycine, D3/K2, beta-alanine, vitamin C) — no clinically meaningful interactions at supplement doses.
• Bromantane, modafinil, selegiline (planned V5 nootropics) — no interaction.
• Standard whey/casein protein, electrolytes, beta-alanine — neutral.

The community-data block in this file enumerates 22 AI-seeded interaction pairs at "caution / low confidence." Most are theoretical and not backed by case reports. Below is the practical filter for what actually matters in a real clinical decision.

Clinically significant (action required):

1. Anticoagulants (warfarin, apixaban, rivaroxaban, dabigatran): Theoretical additive bleeding risk via cordycepin/adenosine antiplatelet effect. No documented case reports of clinically significant bleeding. Action: avoid concurrent use if on therapeutic anticoagulation; if combining, monitor INR (warfarin) or bleeding signs. For Dylan: not applicable.

2. Antidiabetic agents (metformin, sulfonylureas, GLP-1 agonists semaglutide/tirzepatide, insulin): Animal evidence of additive hypoglycemic effect with cordyceps polysaccharides. Action: monitor blood glucose if combining; reduce diabetic medication dose if needed. Type 1 diabetics: take this seriously. Type 2 diabetics on stable metformin: monitor first 2 weeks. For Dylan: not applicable.

3. Levothyroxine / liothyronine (thyroid replacement): Two distinct mechanisms — (a) cordyceps preparations may reduce thyroid autoantibody titers in Hashimoto's, potentially altering levothyroxine requirements; (b) some unregulated cordyceps products have been documented to contain exogenous thyroid hormone as an adulterant. Action: TSH monitoring at 6-8 weeks if combining; source from reputable vendor. For Dylan: not applicable.

4. SSRIs / SNRIs (citalopram, escitalopram, sertraline, venlafaxine, paroxetine): Theoretical serotonergic interaction based on cordyceps's mild monoaminergic effects in animal models. No case reports of serotonin syndrome. Action: monitor mood and side effects, especially in the first 2 weeks of combining. For Dylan: not currently applicable.

5. Hormone therapy (estradiol, testosterone replacement): Cordyceps upregulates steroidogenic enzymes (P450scc) and may inhibit androgen catabolism in animal models. May increase serum levels of exogenous hormones modestly. Action: TRT/HRT users monitor levels at 6-8 weeks. For Dylan: not currently applicable.

Theoretical / low practical concern:

• Triptans (sumatriptan etc.), bupropion, donepezil, trazodone — all flagged at "low confidence" in community data based on single-source mechanistic extrapolation. Practical risk minimal at supplement doses.

Cordyceps has no established pharmacogenomic markers for response or adverse effects. Unlike modafinil (CYP2D6/CYP2C19 status), atomoxetine (CYP2D6), or warfarin (CYP2C9/VKORC1), cordyceps doesn't have a clean polymorphism story for two reasons:

1. The bioactives (cordycepin, polysaccharides) have minimal hepatic CYP metabolism. Cordycepin is primarily deaminated by adenosine deaminase (ADA) in gut/liver. ADA polymorphisms exist (rs73598374, rs244072) but their effect on cordycepin pharmacokinetics is uncharacterized in humans.

2. Polysaccharides aren't absorbed intact — they're partially fermented in the gut. The relevant variability is gut microbiome composition, not host genetics.

Possible pharmacogenomic signals worth tracking in 23andMe data:

• ADORA2A polymorphisms (rs5751876) — adenosine A2A receptor variants affect caffeine sensitivity and might modulate cordyceps response via adenosine-receptor cross-reactivity. Speculative.
• PPAR-γ variants — cordyceps modulates PPAR signaling; PPAR-γ Pro12Ala (rs1801282) might affect immune-axis response. Speculative.

Practical implication for Dylan: When 23andMe results land in June, no actionable cordyceps gene calls. Cordyceps responder status will be determined by 8-week trial, not genotype.

The single most important sourcing rule: buy fruiting body, not mycelium-on-grain. US supplement-industry analyses (Nammex, Real Mushrooms) have shown that ~50-80% of "cordyceps" products on Amazon are mycelium grown on rice or oat substrate, dried and sold as-is. Bulk analysis shows these products are mostly starch (β-1,4-glucan from the grain) rather than actual fungal β-1,3-glucan. Cordycepin content in these products is often near zero.

For Dylan specifically: Real Mushrooms Cordyceps-M (200g powder) — about $50 — runs ~3 months at 2 g/day. Cleanest cost-per-dose option from a reputable supply chain. Skip wild Cs-4 — the price premium ($100-500 per gram for "authentic" Tibetan) buys cultural cachet, not better outcomes, and the contamination risk is real.

Form factor:

• Powder is most cost-efficient. Mix into morning coffee, smoothie, or plain water.
• Capsules are convenient for travel; calculate dose per capsule (most are 500-1000 mg).
• Mushroom coffee/tea blends are pleasant but under-dosed for ergogenic effect.

Quality marker checklist (read the label):

1. Species: Cordyceps militaris (or "Cs-4 strain") — not generic "cordyceps" or "C. sinensis" unless wild-harvested (skip).
2. Fruiting body explicitly — not "mycelium" or "mushroom blend" or "biomass".
3. Standardization: cordycepin ≥0.3% AND/OR β-glucans ≥30%.
4. Third-party testing (heavy metals, microbials) — Nammex-supplied brands publish COAs.

Baseline (before starting)

• Subjective cardio benchmark: Mile time, 5-min row, or 5-round shadowboxing perceived exertion (RPE 1-10). Pre-cordyceps baseline.
• Resting heart rate (Oura / chest strap): 7-day morning average.
• HRV trend: Same 7-day window.
• Sleep quality VAS: 1-10 daily for a week.
• Body weight + body composition: No expected change but useful for confounding control.
• CBC + ferritin + TSH: From the June 2026 bloodwork panel. Anemia or hypothyroidism would mask cordyceps effects.
• (Optional) Pre-cordyceps photo of supplement-free urine: For visual contrast vs adenosine-load.

During use (weeks 1-12)

• Weekly perceived cardio improvement (1-10 VAS): Self-reported. Expect nothing in weeks 1-2; possible signal in week 3-4.
• Same cardio benchmark at week 4 and week 8: Mile time, 5-min row, or comparable test. Effect size to look for: 5-10% improvement.
• Resting HR + HRV monthly: Should drift slightly favorably in a heavy-cardio block (HR down, HRV up).
• Recovery markers (CK if testing, perceived soreness, sleep score): Most likely place to see a signal per the 2026 narrative review.
• GI tolerance + dry mouth: Daily 1-10 in week 1-2, weekly after.

Post-cycle (if cycling off)

• Cardio benchmark after 2 weeks off cordyceps: Did the gain stay (training adaptation), regress (cordyceps-dependent), or stay flat (no effect)? This is the cleanest n=1 responder test.
• Subjective baseline check: "How am I feeling at week 14 vs week 12?" Calibrates placebo vs real benefit.